DOT Physicals
Request Appointment
Facebook Twitter Linkedin Find Us On Tik Tok TikTok

Tirosint® generic is Levothyroxine Sodium Capsules Levothyroxine Sodium Capsules USP, an authorized generic of Tirosint®. Levothyroxine sodium is indicated for the treatment of hypothyroidism –

Tirosint® generic is Levothyroxine Sodium Capsules

Levothyroxine Sodium Capsules USP, an authorized generic of Tirosint®.

Levothyroxine sodium is indicated for the treatment of hypothyroidism – as replacement therapy in primary, secondary, and tertiary congenital or acquired hypothyroidism.

Levothyroxine Sodium Capsules, a unique gel-cap formulation designed to address concerns of absorption and tolerability commonly found in levothyroxine tablets. The capsules contain only four simple ingredients: levothyroxine, gelatin, glycerin and water, and are free from sugars, dyes, alcohol, wheat starch (gluten), and lactose[i]. This is especially important for patients with hypothyroidism who have allergies or sensitivities to ingredients commonly found in levothyroxine tablets or for those with certain gastrointestinal conditions.[ii]

When patients were switched from levothyroxine tablets to gel caps, the majority experienced significant reductions in dose changes and significant improvement in hypothyroid symptom control.[iii]

The results of the study were consistent regardless of the reason for medication switch (efficacy or adverse effects) or prior therapy (branded or generic levothyroxine tablets).3

The generic product is available as 13mcg, 25mcg, 50mcg, 75mcg, 88mcg, 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, and 200mcg strength capsules.   

[1] Levothyroxine Sodium Capsules. Parsippany, NJ: YARAL Pharma Inc; 2021.

[1] McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy; results of the CONTROL Surveillance Project. Drugs in R&D. 2015;16(1):53-68.

[1] Ernst FR, Sandulli W, Elmor R, Welstead J, Sterman AB, Lavan M. Retrospective Study of Patients Switched from Tablet Formulations to a Gel Cap Formulation of Levothyroxine: Results of the CONTROL Switch Study. Drugs R D. 2017 Mar;17(1):103-115. doi: 10.1007/s40268-016-0150-z. PMID: 27943146; PMCID: PMC5318319.

Tirosint® generic is Levothyroxine Sodium Capsules

Levothyroxine Sodium Capsules USP, an authorized generic of Tirosint®.

Levothyroxine sodium is indicated for the treatment of hypothyroidism – as replacement therapy in primary, secondary, and tertiary congenital or acquired hypothyroidism.

Levothyroxine Sodium Capsules, a unique gel-cap formulation designed to address concerns of absorption and tolerability commonly found in levothyroxine tablets. The capsules contain only four simple ingredients: levothyroxine, gelatin, glycerin and water, and are free from sugars, dyes, alcohol, wheat starch (gluten), and lactose[i]. This is especially important for patients with hypothyroidism who have allergies or sensitivities to ingredients commonly found in levothyroxine tablets or for those with certain gastrointestinal conditions.[ii]

When patients were switched from levothyroxine tablets to gel caps, the majority experienced significant reductions in dose changes and significant improvement in hypothyroid symptom control.[iii]

The results of the study were consistent regardless of the reason for medication switch (efficacy or adverse effects) or prior therapy (branded or generic levothyroxine tablets).3

The generic product is available as 13mcg, 25mcg, 50mcg, 75mcg, 88mcg, 100mcg, 112mcg, 125mcg, 137mcg, 150mcg, 175mcg, and 200mcg strength capsules.   

[1] Levothyroxine Sodium Capsules. Parsippany, NJ: YARAL Pharma Inc; 2021.

[1] McMillan M, Rotenberg KS, Vora K, et al. Comorbidities, concomitant medications, and diet as factors affecting levothyroxine therapy; results of the CONTROL Surveillance Project. Drugs in R&D. 2015;16(1):53-68.

[1] Ernst FR, Sandulli W, Elmor R, Welstead J, Sterman AB, Lavan M. Retrospective Study of Patients Switched from Tablet Formulations to a Gel Cap Formulation of Levothyroxine: Results of the CONTROL Switch Study. Drugs R D. 2017 Mar;17(1):103-115. doi: 10.1007/s40268-016-0150-z. PMID: 27943146; PMCID: PMC5318319.